行情

HALO

HALO

奥洛兹美医疗
NASDAQ

实时行情|Nasdaq Last Sale

29.27
+0.25
+0.86%
盘后: 29.03 -0.24 -0.82% 19:33 08/06 EDT
开盘
29.18
昨收
29.02
最高
29.64
最低
28.96
成交量
91.02万
成交额
--
52周最高
29.64
52周最低
12.71
市值
39.75亿
市盈率(TTM)
-52.2492
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测HALO价格均价为30.00,最高价位39.00,最低价为13.00。

EPS

HALO 新闻

更多
Halozyme To Present At Canaccord Genuity 40th Annual Growth Conference
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the upcoming Canaccord Genuity 40th Annual Growth Conference. Dr. Torley will take part in a fireside chat at 8:30 a.m.
PR Newswire · 2天前
Subcutaneous version of J&J's Darzalex OK'd in Canada
Health Canada has approved a subcutaneous formulation of Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies' multiple myeloma med Darzalex
seekingalpha · 2天前
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 3天前
Halozyme To Host Second Quarter 2020 Financial Results Webcast And Conference Call
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2020 on Monday, August 10 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the sa
PR Newswire · 07/29 20:05
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:32
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 07/28 12:24
Did Hedge Funds Make The Right Call On Halozyme Therapeutics, Inc. (HALO) ?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are
Insider Monkey · 07/17 17:30
Drug Stock May Be Overdue for a Short Squeeze
Schaeffer's Investment Research · 07/09 19:46

所属板块

生物技术和医学研究
-0.96%
制药与医学研究
-0.46%

热门股票

代码
价格
涨跌幅

HALO 简况

Halozyme Therapeutics, Inc.是一家专注于肿瘤治疗方法的开发和商业化的生物技术公司。该公司通过酶的研究、开发和商业化业务部门运营。该业务部门还根据与第三方签订的合作协议研究、开发和批量生产rHuPH20,并销售重组Hylenex。该公司开发的产品包括处于临床阶段的肿瘤治疗候选药物。该公司的首个肿瘤治疗项目是PEGPH20(PEGylated重组人透明质酸酶)。该公司开发的PEGPH20被用来系统性的治疗肿瘤,PEGPH20能够集聚透明质酸。该公司用于治疗IV期胰腺导管腺癌的PEGPH20,目前正处于II期和III期临床实验研究阶段(研究109-202和109-301)。用于治疗非小细胞肺癌(研究107-201)的PEGPH20正处于Ib期临床实验研究阶段。用于治疗非小细胞肺癌和胃癌(研究107-101)的PEGPH20正处于Ib期临床实验研究阶段。
展开

微牛提供Halozyme Therapeutics, Inc.(NASDAQ-HALO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的HALO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易HALO股票基本功能。